Back to resultsChemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid Cancer
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
About this trial
This is an interventional treatment trial for Leukemia focused on measuring recurrent childhood acute myeloid leukemia, recurrent adult acute myeloid leukemia, accelerated phase chronic myelogenous leukemia, blastic phase chronic myelogenous leukemia, untreated adult acute myeloid leukemia, untreated childhood acute myeloid leukemia and other myeloid malignancies, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, chronic myelomonocytic leukemia, previously treated myelodysplastic syndromes, secondary myelodysplastic syndromes, childhood chronic myelogenous leukemia, atypical chronic myeloid leukemia, BCR-ABL1 negative, myelodysplastic/myeloproliferative neoplasm, unclassifiable, adult acute myeloid leukemia with t(8;21)(q22;q22), adult acute myeloid leukemia with t(16;16)(p13;q22), adult acute myeloid leukemia with inv(16)(p13;q22), adult acute myeloid leukemia with 11q23 (MLL) abnormalities, adult acute myeloid leukemia with t(15;17)(q22;q12), childhood myelodysplastic syndromes
Eligibility Criteria
DISEASE CHARACTERISTICS: One of the following diagnoses: Pathologically confirmed acute myeloid leukemia (AML) meeting one of the following criteria: Newly diagnosed AML, over age 60, and not eligible for higher priority protocols Newly diagnosed AML and unable to receive anthracycline-containing or high-dose cytarabine-containing regimens AML in relapse AML refractory to two courses of standard induction chemotherapy or one course of high-dose cytarabine-containing induction chemotherapy Chronic myelogenous leukemia in accelerated phase or myeloid blast crisis Refractory anemia with excess blasts (RAEB), RAEB in transformation, or chronic myelomonocytic leukemia More than 25% of bone marrow blasts must be CD33 positive Not a candidate for immediate bone marrow transplantation with a HLA-compatible donor No active CNS leukemia PATIENT CHARACTERISTICS: Age: Not specified Performance status: Karnofsky 60-100% Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Bilirubin no greater than 2 mg/dL (unless due to leukemia or Gilbert's disease) Alkaline phosphatase no greater than 2.5 times upper limit of normal (ULN) AST no greater than 2.5 times ULN Renal: Creatinine less than 2 mg/dL OR Creatinine clearance greater than 60 mL/min Cardiovascular: No New York Heart Association class III or IV cardiac disease Pulmonary: No pulmonary disease Other: No detectable antibodies to monoclonal antibody M195 No serious active uncontrolled infection No other concurrent active malignancy requiring therapy No other serious or life-threatening conditions that would preclude study Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: At least 3 weeks since prior biologic therapy and recovered Chemotherapy: See Disease Characteristics Prior hydroxyurea allowed if discontinued before study treatment At least 3 weeks since other prior chemotherapy and recovered Endocrine therapy: Not specified Radiotherapy: At least 3 weeks since prior radiotherapy and recovered Surgery: Not specified
Sites / Locations
- Memorial Sloan - Kettering Cancer Center
Arms of the Study
Arm 1
Experimental
bismuth Bi 213 monoclonal antibody M195 & cytarabine
Patients receive cytarabine IV continuously on days 1-5. Beginning between days 7 and 14, patients receive Bi213 MOAB M195 IV over 5 minutes up to 4 times daily over 1-4 days. Patient also receive filgrastim (G-CSF) subcutaneously daily beginning 24 hours after the final Bi213 MOAB M195 infusion and continuing until blood counts recover. Treatment continues in the absence of disease progression or unacceptable toxicity. Cohorts of 3 to 6 patients receive escalating doses of Bi213 MOAB M195 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, subsequent patients are treated at the MTD. Patients are followed twice weekly for 4 weeks and then monthly for 3 months
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
1. Study Identification
2. Study Status
3. Sponsor/Collaborators
4. Oversight
5. Study Description
6. Conditions and Keywords
7. Study Design
8. Arms, Groups, and Interventions
10. Eligibility
12. IPD Sharing Statement
Learn more about this trial
